Fig. 1From: Liquid biopsy: a powerful tool to monitor trastuzumab resistance in HER2-positive metastatic gastric cancerLongitudinal circulating tumor DNA sequencing provides novel insights into gene alterations underlying trastuzumab resistance in HER2-positive metastatic gastric cancer. HER2+: HER2-positive; mGC: metastatic gastric cancer; ctDNA: circulating tumor DNA: Copy No.: copy numberBack to article page